酶替代使用beta-D-galactosidase乳糖吸收不良。

文章的细节

引用

复制到剪贴板

科林斯DiPalma是的,女士

酶替代使用beta-D-galactosidase乳糖吸收不良。

中国新药杂志。1989年6月,11 (3):290 - 3。

PubMed ID

2502573 (在PubMed

]

文摘

我们评估10健康症状乳糖malabsorbers效果的口服beta-D-galactosidase来自米曲霉(Lactrase,克雷默城市公司,密尔沃基,WI,美国)症状和呼吸氢气反应与乳糖50克的挑战。基底和每隔30分钟8 h后乳糖挑战,end-alveolar呼吸样本收集和分析氢使用气相色谱法。症状得分在30分钟和每小时8 h,评级腹胀、痉挛、恶心、疼痛、腹泻、肠胃气胀。四个挑战4天分别进行至少3天之间的挑战。前两个挑战作为基线。前摄入乳糖粉50克溶于200毫升水,beta-D-galactosidase胶囊是口服250毫克剂量的第三个挑战4和500毫克剂量的挑战。氢排泄,量化利用梯形法计算面积的不连续的曲线呼吸氢离子的浓度,减少在受试者接受beta-D-galactosidase(基线,346.0 ppm / h;基线II, 367.2 ppm / h;250毫克牛乳糖208.2 ppm / h;500毫克牛乳糖,178.0 ppm / h; p less than or equal to 0.05). Other analyzed parameters of H2 excretion were also decreased. Analysis of symptom response scores showed a dose-related decrease for bloating and flatus (p less than or equal to 0.05) and no statistical difference in the other assessed symptoms. We conclude that beta-D-galactosidase from Aspergillus oryzae, when given just before ingestion of lactose by lactose malabsorbers, can produce a dose-dependent reduction (statistically significant for the 500-mg dose) in breath hydrogen excretion, bloating, and flatus.

DrugBank数据引用了这篇文章

药物

Tilactase